Axsome Therapeutics Stock News

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

There are tangible near-term risks to the business in the face of the coronavirus pandemic, but investors with a long-term mindset could find this pharma stock attractive.

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CareDx (CDNA), ObsEva SA (OBSV) and Axsome Therapeutics

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CareDx ( CDNA – Research Report ), ObsEva SA ( OBSV – Research Report ) and Axsome Therapeutics ( A

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics (AXSM), with a price target of $200.00. The

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics ( AXSM – Research Report ), with a price target of $200.00 . The company’s shares clos

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacte

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccin

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off. The week was light on news flow, barring some smid-cap earnings and...

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.

Fear mounts as investors brace for a viral outbreak in the US. Volatility to remain high as Covid-19 virus remains an unknown threat. Impact on earnings outlook

As I forecasted, the company recently reported robust interim data for U2 in non-Hodgkin lymphoma. Following its strong data report, TG will file a rolling new